Logo

ATR

AptarGroup, Inc.

ATR

AptarGroup, Inc. • NYSE
$124.75 ▲ 0.76% (+0.94)
Market Cap $8.25 B
52w High $174.10
52w Low $103.23
Dividend Yield 1.83%
P/E 20.02
Volume 315.68K
Outstanding Shares 66.12M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $961.131M ▼ $148.76M ▼ $127.785M ▲ 13.295% ▲ $1.95 ▲ $242.893M ▲
Q2-2025 $966.009M ▲ $151.139M ▼ $111.72M ▲ 11.565% ▲ $1.69 ▲ $220.468M ▲
Q1-2025 $887.305M ▲ $222.966M ▲ $78.798M ▼ 8.881% ▼ $1.19 ▼ $183.013M ▼
Q4-2024 $848.088M ▼ $209.307M ▼ $100.944M ▲ 11.903% ▲ $1.52 ▲ $194.894M ▼
Q3-2024 $909.291M $212.483M $100.039M 11.002% $1.51 $210.436M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $264.815M ▲ $5.101B ▲ $2.289B ▲ $2.797B ▲
Q2-2025 $169.765M ▲ $4.865B ▲ $2.148B ▲ $2.7B ▲
Q1-2025 $136.821M ▼ $4.527B ▲ $1.976B ▲ $2.538B ▲
Q4-2024 $226.181M ▼ $4.432B ▼ $1.946B ▼ $2.472B ▼
Q3-2024 $327.911M $4.625B $2.072B $2.539B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $127.847M ▲ $177.606M ▲ $-88.346M ▼ $7.112M ▲ $95.329M ▲ $114.293M ▲
Q2-2025 $111.732M ▲ $125.958M ▲ $-69.438M ▼ $-27.265M ▲ $35.889M ▲ $61.002M ▲
Q1-2025 $78.663M ▼ $82.742M ▼ $-56.632M ▲ $-134.777M ▼ $-98.005M ▲ $23.405M ▼
Q4-2024 $100.865M ▲ $178.239M ▼ $-171.065M ▼ $-87.694M ▼ $-101.18M ▼ $107.707M ▼
Q3-2024 $99.922M $229.262M $-80.67M $-48.641M $104.032M $149.47M

Revenue by Products

Product Q1-2022Q2-2022Q3-2022Q4-2022
Beauty And Home
Beauty And Home
 $370.00M ▲$370.00M ▲$360.00M ▼$340.00M ▼
Food Beverage
Food Beverage
 $130.00M ▲$130.00M ▲$130.00M ▲$120.00M ▼
Pharma
Pharma
 $340.00M ▲$340.00M ▲$340.00M ▲$340.00M ▲

Five-Year Company Overview

Income Statement

Income Statement AptarGroup’s income statement shows steady, healthy growth rather than rapid swings. Sales have inched higher each year, and profits have grown faster than sales, suggesting better pricing power, mix shift toward higher-margin pharma, and improved efficiency. Earnings per share have climbed meaningfully over the period, even through uneven macro conditions, which points to a resilient business model. Overall, this looks like a company gradually widening its profit margin in a disciplined way, not a boom‑and‑bust story.

Balance Sheet

Balance Sheet The balance sheet appears conservative and stable. Total assets have grown slowly, and shareholders’ equity has built up over time, which indicates that profits are being retained and reinvested. Debt levels have been fairly steady to slightly lower, so leverage does not look aggressive. Cash on hand is adequate but not large, which keeps some financial flexibility while still encouraging capital deployment. In short, the company looks reasonably well-capitalized with a balanced approach to debt and equity.

Cash Flow

Cash Flow Cash generation has generally strengthened, with operating cash flow clearly trending upward. Free cash flow has improved over time despite consistently heavy investment in plants, equipment, and innovation. There was a weaker patch a few years ago when free cash flow was tight, but since then the company has translated more of its accounting profits into actual cash. The picture is of a business willing to spend heavily to support growth and technology while still leaving a growing cushion of surplus cash.

Competitive Edge

Competitive Edge AptarGroup benefits from a layered competitive moat. It combines a very large patent portfolio, deep regulatory know‑how in drug delivery, and long-standing relationships with major global brands. Its presence across pharma, beauty, and closures adds resilience, with pharma providing a more defensive, higher‑value anchor. A broad manufacturing footprint close to customers supports service quality and switching costs. Its focus on sustainability and regulatory-compliant designs (for example, tethered caps and specialized drug delivery devices) further differentiates it, making it harder for low‑cost rivals to match the full value proposition.

Innovation and R&D

Innovation and R&D Innovation is a central pillar for AptarGroup. The company has thousands of patents and a sizeable share of its pharma workforce devoted to research and development. It has built strong positions in advanced dispensing systems, active packaging that protects sensitive drugs and consumer products, and specialized drug delivery technologies such as nasal sprays used in critical therapies. More recently, it has pushed into digital health, smart inhalers, connected drug delivery, and software for disease management. This blend of physical devices, material science, and digital platforms suggests a long runway for new product introductions but also requires ongoing high investment and careful execution.

Summary

Overall, AptarGroup combines steady financial performance with a strong innovation engine and a defensible niche in healthcare-related packaging and delivery systems. The income statement shows gradual growth and margin improvement, the balance sheet looks sound and not overly leveraged, and cash flow supports both investment and financial flexibility. Competitively, its patents, regulatory expertise, global scale, and sustainability focus create real barriers to entry, particularly in pharma. Looking ahead, the biggest opportunities lie in digital health, connected drug delivery, and sustainable packaging solutions, while key risks include regulatory shifts, the need to keep R&D payoffs high, and potential demand swings in more discretionary end-markets like beauty and consumer packaging.

NEWS

November 11, 2025 · 5:00 PM UTC

Aptar to Present at Jefferies Global Healthcare Conference on November 19, 2025

Read more

October 30, 2025 · 5:00 PM UTC

Aptar Reports Third Quarter 2025 Results

Read more

October 27, 2025 · 4:00 AM UTC

Rakovina Therapeutics Showcases Potent AI-Developed ATR Inhibitors with CNS Penetrance at AACR-NCI-EORTC International Conference

Read more

September 16, 2025 · 7:00 AM UTC

CytoSorbents Provides DrugSorb-ATR Regulatory Update

Read more

September 8, 2025 · 5:00 PM UTC

Aptar Increases Quarterly Dividend by Nearly 7% Signaling Continued Momentum and Long-Term Strength

Read more